All In Biotech

Drug Trial Radar · NCT07843641

A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST)

A Phase 2, StrateGIST Legacy Study to Provide Continued Treatment With Velzatinib to Participants With Gastrointestinal Stromal Tumors (GIST) Who Have Completed a Velzatinib Parent Study

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Oct 13, 2026

Primary completion

Jan 31, 2031

Study completion Jan 31, 2031

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Sep 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the long-term safety and tolerability of velzatinib (GSK6042981) in adults with GIST who have previously received velzatinib in parent study and continue to benefit from the treatment. Participants will be monitored for side effects and overall health to better understand the effects of long-term treatment and support future care for adults with GIST.

Conditions

  • Gastrointestinal Neoplasms

Interventions

  • VelzatinibDrug

    Velzatinib will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: Up to 224 weeks
  2. Duration of TEAEs and SAEsTime frame: Up to 224 weeks
  3. Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) by severityTime frame: Up to 224 weeks
  4. Number of participants with adverse events or serious adverse events leading to dose modification or study intervention discontinuationTime frame: Up to 224 weeks
  5. Number of participants with clinically significant changes in vital signs, laboratory parameters, cardiac function, and Eastern Cooperative Oncology Group (ECOG) performance status changesTime frame: Up to 224 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.